BioXcel Therapeutics (BTAI) Retained Earnings (2017 - 2026)

BioXcel Therapeutics' Retained Earnings history runs 10 years deep, the most recent figure standing at -$732.8 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 11.46% year-over-year to -$732.8 million in Q1 2026; TTM through Mar 2026 was -$732.8 million, a 11.46% decrease from a year earlier, with the FY2025 full-year figure at $624.6 million, up 12.12% from the prior year.
• Retained Earnings slipped to -$732.8 million in Q1 2026 per BTAI's latest filing, from $624.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $624.6 million in Q4 2025 and bottomed at -$732.8 million in Q1 2026.
• The 5-year median for Retained Earnings is $479.2 million (2022), against an average of $40.3 million.
• Across the five-year window, Retained Earnings surged 385.2% in 2022 and sank 227.79% in 2025, its largest moves.
• Year by year, Retained Earnings stood at $488.3 million in 2022, then plunged by 220.95% to -$590.6 million in 2023, then surged by 194.32% to $557.0 million in 2024, then gained by 12.12% to $624.6 million in 2025, then slumped by 217.33% to -$732.8 million in 2026.
• Per Business Quant, the three latest BTAI Retained Earnings figures stand at -$732.8 million (Q1 2026), $624.6 million (Q4 2025), and -$707.5 million (Q3 2025).